Adaptimmune Therapeutics plc (ADAP) Financial Statements (2025 and earlier)

Company Profile

Business Address 60 JUBILEE AVENUE
ABINGDON, OXFORDSHIRE, OX14 4RX
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments214,789143,652146,938161,728204,707165,554
Cash and cash equivalents211,810140,670143,99190,05976,969119,866
Short-term investments2,9792,9822,94771,669127,73845,688
Receivables2,64010,1958212,1613,0622,070
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Prepaid expense10,6519,8549,95411,97313,0406,787
Other current assets3,2872,8372,4121,6831,7651,664
Other undisclosed current assets22,40320,36547,42741,82339,19737,673
Total current assets:253,770186,903207,552219,368261,771213,748
Noncurrent Assets
Operating lease, right-of-use asset18,20319,43420,76221,30222,02717,947
Property, plant and equipment45,86748,29150,94652,57155,49254,365
Intangible assets, net (including goodwill)996524330384463443
Intangible assets, net (excluding goodwill)996524330384463443
Restricted cash and investments2,8662,8583,0263,0133,2311,578
Other noncurrent assets      
Total noncurrent assets:67,93271,10775,06477,27081,21374,333
TOTAL ASSETS:321,702258,010282,616296,638342,984288,081
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities38,36329,63738,43140,75339,95538,397
Accounts payable7,5136,5878,12813,92214,7135,187
Accrued liabilities30,85023,05030,30326,83125,24233,210
Deferred revenue38,41731,52428,97329,31231,41822,304
Other liabilities 107     
Other undisclosed current liabilities5,1865,2505,3845,0814,7522,930
Total current liabilities:82,07366,41172,78875,14676,12563,631
Noncurrent Liabilities
Long-term debt and lease obligation24,954     
Long-term debt, excluding current maturities24,954     
Liabilities, other than long-term debt118,401167,224170,315133,363140,208140,574
Deferred revenue99,860147,365149,060111,487117,257119,251
Other liabilities1,4401,4171,4041,3561,3611,332
Operating lease, liability17,10118,44219,85120,52021,59019,991
Total noncurrent liabilities:143,355167,224170,315133,363140,208140,574
Total liabilities:225,428233,635243,103208,509216,333204,205
Equity
Equity, attributable to parent96,27424,37539,51388,129126,65183,876
Common stock2,0832,0811,8651,8631,8511,407
Additional paid in capital1,099,7581,096,6901,064,5691,061,4201,057,547992,520
Accumulated other comprehensive income (loss)(3,412)(2,720)(3,748)102(3,092)(1,785)
Accumulated deficit(1,002,155)(1,071,676)(1,023,173)(975,256)(929,655)(908,266)
Total equity:96,27424,37539,51388,129126,65183,876
TOTAL LIABILITIES AND EQUITY:321,702258,010282,616296,638342,984288,081

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues128,2315,6782317,3195,13047,601
Gross profit:128,2315,6782317,3195,13047,601
Operating expenses(59,531)(54,939)(50,087)(53,952)(50,038)(45,945)
Operating income (loss):68,700(49,261)(49,856)(46,633)(44,908)1,656
Nonoperating income (expense)497(61)(313)(324)22,656(671)
Investment income, nonoperating     22,155 
Other nonoperating income (expense)497(61)(313)(324)501(671)
Interest and debt expense(526)     
Income (loss) from continuing operations before equity method investments, income taxes:68,671(49,322)(50,169)(46,957)(22,252)985
Other undisclosed income from continuing operations before income taxes1,3761,3451,5962,0431,543676
Income (loss) from continuing operations before income taxes:70,047(47,977)(48,573)(44,914)(20,709)1,661
Income tax expense (benefit)(526)(526)656(687)(680)(625)
Net income (loss) available to common stockholders, basic:69,521(48,503)(47,917)(45,601)(21,389)1,036
Other undisclosed net income available to common stockholders, diluted      
Net income (loss) available to common stockholders, diluted:69,521(48,503)(47,917)(45,601)(21,389)1,036

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income (loss):69,521(48,503)(47,917)(45,601)(21,389)1,036
Comprehensive income (loss):69,521(48,503)(47,917)(45,601)(21,389)1,036
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(692)1,028(3,850)3,194(1,306)(910)
Comprehensive income (loss), net of tax, attributable to parent:68,829(47,475)(51,767)(42,407)(22,695)126

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: